Newsfeeds - Spark Newswire

1 minute read

Jefferies Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $8

Today, 3:08 AM

Jefferies analyst Maury Raycroft initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $8.

CMPX

2 minute read

Analyst Ratings

Expert Ratings for Compass Therapeutics

By Benzinga Insights

Today, 3:08 AM

Compass Therapeutics (NASDAQ:CMPX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

CMPX

1 minute read

Stifel Initiates Coverage On Compass Therapeutics with Buy Rating, Announces Price Target of $9

By Benzinga Newsdesk

Today, 3:08 AM

Stifel analyst Stephen Willey initiates coverage on Compass Therapeutics (NASDAQ:CMPX) with a Buy rating and announces Price Target of $9.

CMPX

3 minute read

Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

Today, 3:08 AM

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.

AHPI

3 minute read

Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast

By Lisa Levin

Today, 3:08 AM

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell 0.11% to 11,352.46. The S&P 500 also fell, dropping, 0.30% to 4,007.66.

BBBY

1 minute read

Compass Therapeutics’ Combo Therapy Shows Around 38% Overall Response Rate In Pretreated Biliary Tract Cancer Patients

By Vandana Singh

Today, 3:08 AM

Compass Therapeutics Inc (NASDAQ: CMPX) announced the presentation of data from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers (BTC).

CMPX

1 minute read

Compass Therapeutics Files Prospectus Relates To Offering, Resale By Selling Stockholders Of Up To 25M Shares Of Common Stock

By Michael Horton

Today, 3:08 AM

-SEC Filing

CMPX

1 minute read

Raymond James Maintains Outperform on Compass Therapeutics, Raises Price Target to $8

By Benzinga Newsdesk

Today, 3:08 AM

Raymond James analyst Dane Leone maintains Compass Therapeutics (NASDAQ:CMPX) with a Outperform and raises the price target from $5 to $8.

CMPX

2 minute read

Compass Therapeutics Announces $80M Private Placement

By Benzinga Newsdesk

Today, 3:08 AM

Compass Therapeutics, Inc. (NASDAQ:CMPX), ("Compass"), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered

CMPX

1 minute read

Compass Therapeutics Q2 EPS $(0.08) Up From $(1.07) YoY

By Benzinga Newsdesk

Today, 3:08 AM

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share. This is a 92.52 percent increase over losses of $(1.07) per share from the same period last year.

CMPX